China Pharma Holdings, Inc.
China Pharma Holdings, Inc. manufactures and sells generic drugs and modern Traditional Chinese Medicines in the People's Republic of China, generating revenue through an academic-driven promotion model targeting medical institutions.
Business. CHINA PHARMA HOLDINGS, INC. (CPHI) is a pharmaceutical company operating within the Healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is headquartered in China and trades on the New York Stock Exchange under the ticker symbol CPHI. Specific details regarding operating segments or geographic revenue breakdowns are not provided.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CHINA PHARMA HOLDINGS, INC. (CPHI) is a pharmaceutical company operating within the Healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is headquartered in China and trades on the New York Stock Exchange under the ticker symbol CPHI. Specific details regarding operating segments or geographic revenue breakdowns are not provided.
China Pharma Holdings presents a fragile capital structure characterized by severe liquidity constraints and negative operating performance. The company reports a current ratio of 0.28, indicating that current liabilities significantly exceed current assets by $5.3 million as of March 31, 2026. Total equity stands at $37.0 million against total liabilities of $8.1 million, resulting in a low debt-to-equity ratio of 0.04. However, the balance sheet is strained by a cash position of only $0.17 million and short-term debt of $1.47 million. Operating cash flow is negative at -$55,292, and the company carries an accumulated deficit of $48.4 million. These metrics confirm the high liquidity risk flagged in the assessment, with net cash negative after subtracting total debt.
Profitability metrics are deeply negative, reflecting the company's pre-profit or turnaround stage. Return on equity is -8.61% and return on assets is -7.06%. The company reported a net loss of $1.14 million on revenue of $983,536 for Q1 2026. Gross profit was $285,487, but operating expenses drove operating income to -$1.12 million. The EV/EBITDA ratio is negative at -9.10, and the EV/Revenue ratio is 3.81. Without cohort median data for direct comparison, these returns indicate a business model that is currently cash-burning and reliant on external capital or operational restructuring to achieve sustainability.
- Liquidity is critically low with a current ratio of 0.28 and only $0.17 million in cash against $1.47 million in short-term debt.
- The company faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $48.4 million.
- Stock price is below the $1.00 minimum-bid threshold for NYSE continued listing, trading at $0.98.
- Dilution risk is medium due to potential equity offerings required to alleviate liquidity constraints.
- Revenue is concentrated in 19 pharmaceutical products in the PRC, exposed to medical insurance cost-control policies.
- Operating cash flow is negative at -$55,292, requiring external capital or successful execution of sales model changes.
Bull / Bear case
Generated · model-assistedFY2025 revenue reached $4.1 million, showing a 9.3% year-over-year increase despite broader operational losses.
The company generated positive free cash flow of $88,937 in FY2025, indicating improved cash generation capabilities.
Debt-to-equity ratio of 0.04 ranks above the cohort median of 0.19, suggesting a conservative capital structure.
Credit risk is assessed as low, implying manageable default probabilities despite current financial performance challenges.
Net income deteriorated to a loss of $3.2 million in FY2025, reflecting worsening profitability trends.
Liquidity risk is rated high, with a current ratio of only 0.32 indicating potential short-term solvency issues.
Revenue declined at a two-year CAGR of -19.6%, signaling a shrinking top-line business trajectory.
Return on equity of -8.6% ranks in the bottom quartile, demonstrating poor capital efficiency relative to peers.
In focus — financials by report
Revenue $983.5k; Operating income -$1.1M.
- ▍Revenue $983.5k
- ▍Operating income -$1.1M
- ▍Net margin -116.2%
Revenue $2.9M; Operating income -$2.0M.
- ▍Revenue $2.9M
- ▍Operating income -$2.0M
- ▍Net margin -67.3%
Revenue $2.2M; Operating income -$1.4M.
- ▍Revenue $2.2M
- ▍Operating income -$1.4M
- ▍Net margin -60.8%
Revenue $4.1M; Operating income -$3.2M.
- ▍Revenue $4.1M
- ▍Operating income -$3.2M
- ▍Net margin -76.9%
Revenue $4.5M; Operating income -$4.6M.
- ▍Revenue $4.5M
- ▍Operating income -$4.6M
- ▍Net margin -104.6%
Revenue $4.5M; Operating income -$4.6M.
- ▍Revenue $4.5M
- ▍Operating income -$4.6M
- ▍Net margin -104.6%
Revenue $7.0M; Operating income -$2.8M.
- ▍Revenue $7.0M
- ▍Operating income -$2.8M
- ▍Net margin -43.9%
Revenue $7.0M; Operating income -$2.8M.
- ▍Revenue $7.0M
- ▍Operating income -$2.8M
- ▍Net margin -43.9%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Current liabilities exceed current assets.
- Net cash is negative after subtracting total debt.
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Capex To Revenuecapital_expenditure / revenue
- CHINA PHARMA HOLDINGS, INC. company facts · 2026-07-21
- CHINA PHARMA HOLDINGS, INC. 10-Q 2026-05-15 · 2026-07-21
- CHINA PHARMA HOLDINGS, INC. 10-K 2026-04-01 · 2026-07-21
- CHINA PHARMA HOLDINGS, INC. 10-Q 2025-11-12 · 2026-07-21
- CHINA PHARMA HOLDINGS, INC. 10-Q 2025-08-14 · 2026-07-21
- ha_price_listing fired on CPHI · 2026-07-21
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)
- Narrative— → —medium
- Business summary— → —medium
- Conclusion— → —medium
- Key takeaways— → —medium
- Company share pct— → —medium
Evidence & claims
From filings & derived data- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 136.5%Derived (calculated)
- Net margin (FY 2025-12-31): -76.9%Derived (calculated)
- Gross margin (FY 2025-12-31): -3.2%Derived (calculated)
- Return on equity (FY 2025-12-31): -14.0%Derived (calculated)
- Return on assets (FY 2025-12-31): -10.3%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.32xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.36xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 54.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -44.9%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -34.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 72.7%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 72.7%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 93.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 32.7%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 29.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -1.1%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -8.5%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 193.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 108.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 15.7%Derived (calculated)
- Total operating expenses (annual): USD 3.11MSEC XBRL filing
- Gross profit (annual): USD -131.95KSEC XBRL filing
- Revenue (annual): USD 4.14MSEC XBRL filing
- Operating cash flow (annual): USD 148.26KSEC XBRL filing